European journal of nuclear medicine and molecular imaging · 2026
Beyond tumor tracing: physiological uptake of sympathetic ganglia on somatostatin receptor PET/CT - prevalence, patterns, and biological rationale.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Meixi, Hong Ruping, Zhang Yuwei, Yan Xinchun, Wang Jingnan, Zhang Haiqiong, Ren Chao, Huang Zhenghai, Shi Jing, Cheng Yuejuan, Tong Anli, Jing Hongli, Zhu Wenjia, Huo Li
Аннотация
PURPOSE: This study aims to investigate the prevalence, pattern, physiological basis, and influencing factors of sympathetic ganglia uptake on [18F]AlF-NOTA-LM3 PET/CT.
METHODS: [18F]AlF-NOTA-LM3 PET/CT images from 101 patients were retrospectively reviewed to evaluate the presence of sympathetic ganglia uptake. Clinical data and normal-organ uptake were investigated to identify influencing factors. Uptake patterns were compared between sympathetic ganglia and metastatic lymph nodes. Immunohistochemical (IHC) staining for SSTR2 was performed on a stellate ganglion and other specimens.
RESULTS: Positive sympathetic ganglia were observed in 76.2% (77/101) of patients on [18F]AlF-NOTA-LM3 PET/CT. 76.2% (77/101), 33.7% (34/101), 23.8% (24/101), 32.7% (33/101) of patients exhibited positive stellate, thoracic, celiac, and sacral ganglia, respectively. Sympathetic ganglia uptake was associated with higher pituitary, adrenal gland, small-intestinal uptake, and lower tumor burden. Sympathetic ganglia generally exhibited a bilateral symmetric distribution and significantly lower uptake than lymph node metastases (SUVmax: 2.29 ± 0.67 vs. 14.52 ± 14.29; P < 0.001). An SUVmax cutoff of 3.45 differentiated sympathetic ganglia from metastatic lymph nodes with an accuracy of 95.9% and an AUC of 0.967. IHC revealed moderate SSTR2 expression in the membrane and cytoplasm of a subset of stellate ganglionic neurons and in neurons of both the myenteric and submucosal plexuses of duodenum.
CONCLUSION: Sympathetic ganglia uptake on SSTR PET/CT is a common physiological finding, featured by symmetric distribution and faint uptake. Histopathology confirming SSTR2-positive ganglionic neurons provides the biological basis for this uptake.
METHODS: [18F]AlF-NOTA-LM3 PET/CT images from 101 patients were retrospectively reviewed to evaluate the presence of sympathetic ganglia uptake. Clinical data and normal-organ uptake were investigated to identify influencing factors. Uptake patterns were compared between sympathetic ganglia and metastatic lymph nodes. Immunohistochemical (IHC) staining for SSTR2 was performed on a stellate ganglion and other specimens.
RESULTS: Positive sympathetic ganglia were observed in 76.2% (77/101) of patients on [18F]AlF-NOTA-LM3 PET/CT. 76.2% (77/101), 33.7% (34/101), 23.8% (24/101), 32.7% (33/101) of patients exhibited positive stellate, thoracic, celiac, and sacral ganglia, respectively. Sympathetic ganglia uptake was associated with higher pituitary, adrenal gland, small-intestinal uptake, and lower tumor burden. Sympathetic ganglia generally exhibited a bilateral symmetric distribution and significantly lower uptake than lymph node metastases (SUVmax: 2.29 ± 0.67 vs. 14.52 ± 14.29; P < 0.001). An SUVmax cutoff of 3.45 differentiated sympathetic ganglia from metastatic lymph nodes with an accuracy of 95.9% and an AUC of 0.967. IHC revealed moderate SSTR2 expression in the membrane and cytoplasm of a subset of stellate ganglionic neurons and in neurons of both the myenteric and submucosal plexuses of duodenum.
CONCLUSION: Sympathetic ganglia uptake on SSTR PET/CT is a common physiological finding, featured by symmetric distribution and faint uptake. Histopathology confirming SSTR2-positive ganglionic neurons provides the biological basis for this uptake.